Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population
Schweizer, A, Dejager, S, Foley, J.E, Couturier, A, Ligueros-Saylan, M, Kothny, W
Published in Diabetes, obesity & metabolism (01.06.2010)
Published in Diabetes, obesity & metabolism (01.06.2010)
Get full text
Journal Article
Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans
Ahrén, B., Schweizer, A., Dejager, S., Villhauer, E. B., Dunning, B. E., Foley, J. E.
Published in Diabetes, obesity & metabolism (01.09.2011)
Published in Diabetes, obesity & metabolism (01.09.2011)
Get full text
Journal Article
Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes
MATIKAINEN, N, MÄNTTÄRI, S, SCHWEIZER, A, ULVESTAD, A, MILLS, D, DUNNING, B. E, FOLEY, J. E, TASKINEN, M.-R
Published in Diabetologia (01.09.2006)
Published in Diabetologia (01.09.2006)
Get full text
Journal Article
Vildagliptin, a Dipeptidyl Peptidase-IV Inhibitor, Improves Model-Assessed β-Cell Function in Patients with Type 2 Diabetes
Mari, A, Sallas, W. M, He, Y. L, Watson, C, Ligueros-Saylan, M, Dunning, B. E, Deacon, C. F, Holst, J. J, Foley, J. E
Published in The journal of clinical endocrinology and metabolism (01.08.2005)
Published in The journal of clinical endocrinology and metabolism (01.08.2005)
Get full text
Journal Article
Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trial
Pan, C., Yang, W., Barona, J. P., Wang, Y., Niggli, M., Mohideen, P., Wang, Y., Foley, J. E.
Published in Diabetic medicine (01.04.2008)
Published in Diabetic medicine (01.04.2008)
Get full text
Journal Article
Enhanced beta cell function and anti-inflammatory effect after chronic treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin in an advanced-aged diet-induced obesity mouse model
Omar, B. A., Vikman, J., Winzell, M. S., Voss, U., Ekblad, E., Foley, J. E., Ahrén, B.
Published in Diabetologia (01.08.2013)
Published in Diabetologia (01.08.2013)
Get full text
Journal Article
Beta cell function following 1 year vildagliptin or placebo treatment and after 12 week washout in drug-naive patients with type 2 diabetes and mild hyperglycaemia: a randomised controlled trial
Foley, J. E., Bunck, M. C., Möller-Goede, D. L., Poelma, M., Nijpels, G., Eekhoff, E. M., Schweizer, A., Heine, R. J., Diamant, M.
Published in Diabetologia (01.08.2011)
Published in Diabetologia (01.08.2011)
Get full text
Journal Article
Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study
Matthews, D.R, Dejager, S, Ahren, B, Fonseca, V, Ferrannini, E, Couturier, A, Foley, J.E, Zinman, B
Published in Diabetes, obesity & metabolism (01.09.2010)
Published in Diabetes, obesity & metabolism (01.09.2010)
Get full text
Journal Article
Study to determine the durability of glycaemic control with early treatment with a vildagliptin-metformin combination regimen vs. standard-of-care metformin monotherapy-the VERIFY trial: a randomized double-blind trial
Del Prato, S., Foley, J. E., Kothny, W., Kozlovski, P., Stumvoll, M., Paldánius, P. M., Matthews, D. R.
Published in Diabetic medicine (01.10.2014)
Published in Diabetic medicine (01.10.2014)
Get full text
Journal Article
assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials
Ligueros-Saylan, M, Foley, J.E, Schweizer, A, Couturier, A, Kothny, W
Published in Diabetes, obesity & metabolism (01.06.2010)
Published in Diabetes, obesity & metabolism (01.06.2010)
Get full text
Journal Article
Adverse effects of dipeptidyl peptidases 8 and 9 inhibition in rodents revisited
Burkey, B. F., Hoffmann, P. K., Hassiepen, U., Trappe, J., Juedes, M., Foley, J. E.
Published in Diabetes, obesity & metabolism (01.11.2008)
Published in Diabetes, obesity & metabolism (01.11.2008)
Get full text
Journal Article
Studies in rodents with the dipeptidyl peptidase-4 inhibitor vildagliptin to evaluate possible drug-induced pancreatic histological changes that are predictive of pancreatitis and cancer development in man
Busch, S. J., Hoffmann, P., Sahota, P., Johnson, R., Kothny, W., Meyer, F., Foley, J. E.
Published in Diabetes, obesity & metabolism (01.01.2013)
Published in Diabetes, obesity & metabolism (01.01.2013)
Get full text
Journal Article
Characterization of Anaplasma phagocytophilum Major Surface Protein 5 and the Extent of Its Cross-Reactivity with A. marginale
Strik, N. I, Alleman, A. R, Barbet, A. F, Sorenson, H. L, Wamsley, H. L, Gaschen, F. P, Luckschander, N, Wong, S, Chu, F, Foley, J. E, Bjoersdorff, A, Stuen, S, Knowles, D. P
Published in Clinical and Vaccine Immunology (01.03.2007)
Published in Clinical and Vaccine Immunology (01.03.2007)
Get full text
Journal Article
A high concentration of fasting plasma non-esterified fatty acids is a risk factor for the development of NIDDM
Paolisso, G, Tataranni, P A, Foley, J E, Bogardus, C, Howard, B V, Ravussin, E
Published in Diabetologia (01.10.1995)
Published in Diabetologia (01.10.1995)
Get more information
Journal Article